Navigation Links
P&G Delivers Second Quarter EPS and Organic Sales in Line with Expectations
Date:1/30/2009

les by about five percent. The net impact of acquisitions and divestitures is estimated to be flat to negative one percent. Total sales growth is expected to be flat to negative four percent.

The Company also stated that it is comfortable with analysts' current consensus earnings per share estimate of $4.29. This approximates the mid- point of the Company's revised Fiscal 2009 guidance range of $4.20 to $4.35 per share. The Company modified the guidance range to reflect the high level of market volatility and uncertainty that exists today. Operating margin, which includes the impact of incremental Folgers-related restructuring charges, is expected to be consistent with the prior fiscal year. The Company's tax rate on continuing operations is expected to be between 27 and 28 percent.

For the January - March quarter, organic sales are expected to grow two to five percent. The combination of pricing and product mix is expected to contribute between five and seven percent to sales growth. Organic volume is expected to decline two to three percent. Foreign exchange is estimated to reduce net sales by high-single-digits, and the net impact of acquisitions and divestitures is expected to be neutral to net sales growth for the quarter. Total sales are expected to be down two to seven percent.

The Company expects earnings per share to be in the range of $0.78 to $0.86 for the quarter, including incremental Folgers-related restructuring charges. Operating margin is expected to decline modestly, as Folgers-related restructuring charges, higher commodity costs and volume de-leveraging should be largely offset by productivity improvements and manufacturing cost savings programs.

Forward Looking Statements

All statements, other than statements of historical fact included in this release, are forward-looking statements, as that term is defined in the Private Securities Litigat
'/>"/>

SOURCE The Procter & Gamble Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Equateq Delivers Pharma-Grade DGLA for Skin Health
2. Senate Finance Committee Delivers Childrens Insurance
3. U.S. House Gets the Job Done for Americas Working Families and Delivers Childrens Insurance
4. Sheffield Teaching Hospitals NHS Foundation Trust delivers same day patient discharge via BigHand Digital Dictation
5. Nothing But Nets Delivers 740,000 Bed Nets to Central African Republic
6. Vivisimo Search Delivers Medical Knowledge to Global Health-Care Community
7. InVitria's Cellastim Delivers Superior Results in CHO Cell Culture
8. New Internet Service Delivers Relief to Families of Those in Long-Term Care
9. New Software Streamlines Interface Management, Delivers More System Security and Greater IT Control
10. Healthplace America Delivers the First and Only Surgery Benefit Management Solution Through the Healthplace Benefit(TM)
11. Analog Devices Healthcare Director Delivers Speech on Role of Analog Semiconductors in Next-Generation Portable Medical Equipment : ADI's Pat O'Doherty is a featured speaker at electronica 2008.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)... iCRco is proud to announce its participat...ceived the highest grade possible amongst all majo... be rated “A” in sales, service and te...faction in software functionality. iCRco is very p...y the most prestigious research firm in medical im...
(Date:11/23/2009)...A,Va.,Nov.23/PRNewswire/--JustintimefortheThanksgi...efswithtipsandrecipesforcookingupadeliciousmeal:de...andhealthinformation, turkeyfrying.net alsopro...aswellaspartyideasfortakingtheturkeybeyondThanksgi...lySouthernwayofdeep-fryingwith100%peanutoil. ,,...
(Date:11/23/2009)...ngs support link between mental and physical healt...- Being depressed might take as many years off you... However, a combination of depression and anxiety ...ssion. , Researchers came to their conclusions ... than 60,000 people. During the four years after t...
(Date:11/23/2009)... fat on their waist in middle age are more than tw...der, reveals a new study from the Sahlgrenska Acad...scientific journal Neurology . , "Anyone carryi...sk of dying prematurely due to a heart attack or s... the Sahlgrenska Academy. "If they nevertheless ma...
(Date:11/23/2009)...ease is caused by the build-up of a brain peptide ...otein has been the focus of almost all drug resear...rative condition. , But that may be counterprodu...y,s Department of Physiology and Pharmacology, Sac...nstrates that amyloid-beta is also necessary to ma...
Breaking Medicine News(10 mins):Health News:iCRco is the Only CR Vendor to Receive the Highest Grade “A” in All Fields by KLAS 2Health News:iCRco is the Only CR Vendor to Receive the Highest Grade “A” in All Fields by KLAS 3Health News:Depression May Up Death Risk to That of Smoking 2Health News:Upending textbook science on Alzheimer's disease 2
...h Organization (WHO) figures show that each year a...B) arise in the world. The growth of this disease ...igh proportion of HIV patients (nearly 13% compare... TB, developed because the virus weakens the immun...
...sion Leverages Personal Health Care Utilization an...Making and Communication -, MARLBOROUGH, Mass., ...sident and general manager of Outsource...atured presenter in the "Getting Personal -- ...
...h., March 5 HealthMedia, the global,leader in sca... experienced,its highest earnings for any single q...ral new contracts, HealthMedia,s healthcare licens...ed 88,percent in 2007, compared to 2006 totals., ...
...tified Juice Beverages for Kids Introduced to Near...de, ATLANTA, March 5 White Hat Brands, makers of...oday that it has teamed up with the,American Camp ...hrough the camp experience., "Our support of the ...
...Wyo., March 5 Physicians Wellness Network,(PWN), ...sumer-selected lab,testing, today announced that i...en easier for widespread, consumer-selected diabet...n for finger-stick blood tests that screen for dia...
...Calif., March 5 Transcept,Pharmaceuticals, Inc. t...,President & Chief Financial Officer, will present...nference at the Boston Marriott Copley Place on,Th...any,deriving significant new patient benefits from...
Other Medicine News:Health News:A new more effective tuberculosis screening test for HIV victims 2Health News:A new more effective tuberculosis screening test for HIV victims 3Health News:Upcoming Business Health Agenda 2008 Features Workscape Executive 2Health News:HealthMedia Fourth Quarter 2007 Produces Highest Revenue in Company History 2Health News:White Hat Brands, American Camp Association Launch Partnership to Advance Children's Wellness 2Health News:Physicians Wellness Network and Home Access Health to Provide Medically Compliant Diabetes Testing Sold Directly to Consumers 2
(Date:11/23/2009)..., NOVATO,Calif.,Nov.23/PRNewswire-FirstCall/-...(Nasdaq: RPTP ),todayannouncedresultsfromaPhase2bc...inebitartrate("DRCysteamine")inpatientswithnephrop...theUniversityofCalifornia,SanDiego("UCSD")GeneralC...,pharmacokineticsandpharmacodynamicsofasingledoseo...
(Date:11/23/2009)..., EMERYVILLE,Calif.,Nov.23/PRNewswire-FirstCa... )("NTI")announcedtodaythatitsboardofdirectorshasd...monstock,whichwillbepaidonDecember9,2009tostockhol...xtraordinarydividendfollowsstockholderapprovalofth...ionanddissolutionandanearlierextraordinarydividend...
(Date:11/20/2009)..., , WAYNE, Pa., Nov. 20 /PRNewswire-FirstCal...announced the results for its fiscal first quarter...uarter of fiscal 2010, product revenue decreased a...ng the three-month period ended September 30, 2009... The Company reported the decreased net revenue of...
Breaking Medicine Technology:Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share 2Escalon(R) Reports First Quarter Fiscal 2010 Results 2Escalon(R) Reports First Quarter Fiscal 2010 Results 3Escalon(R) Reports First Quarter Fiscal 2010 Results 4Escalon(R) Reports First Quarter Fiscal 2010 Results 5Escalon(R) Reports First Quarter Fiscal 2010 Results 6Escalon(R) Reports First Quarter Fiscal 2010 Results 7Reminder program dramatically increases mammography rates Kaiser Permanente study finds 51578 1Reminder program dramatically increases mammography rates Kaiser Permanente study finds 51578 2Reminder program dramatically increases mammography rates Kaiser Permanente study finds 51578 3FAIR CEO Blasts Kaiser Foundation 26amp 3B Public Agenda HIV AIDS Study Results as 26quot 3BAbsolute Nonsense 26quot 3B 51573 1FAIR CEO Blasts Kaiser Foundation 26amp 3B Public Agenda HIV AIDS Study Results as 26quot 3BAbsolute Nonsense 26quot 3B 51573 2FAIR CEO Blasts Kaiser Foundation 26amp 3B Public Agenda HIV AIDS Study Results as 26quot 3BAbsolute Nonsense 26quot 3B 51573 3FAIR CEO Blasts Kaiser Foundation 26amp 3B Public Agenda HIV AIDS Study Results as 26quot 3BAbsolute Nonsense 26quot 3B 51573 4Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 1Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 2Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 3Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 4Eliminating polio requires global coordinated effort Health Affairs article highlights risks rewards of eradication 51569 5
...pr 16, 2007 - Amgen,(Nasdaq:AMGN) today presented ...bo-controlled Phase 3 study evaluating the,efficac...the,treatment of anemia in patients with active ca...the 103 study"). Aranesp is not,approved for use b... were presented in an oral session at the 2007 Ame...
...nt not met; plausibly,confounded by survival benef...K, April 16, 2007 /PRNewswire-FirstCall/ -- ImClon...mpany today,announced detailed results from the EP...Phase III trial - comparing ERBITUX(R),(Cetuximab)...ith,metastatic colorectal cancer (mCRC) who failed...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
...nce laboratory and a worldwide leader in innovativ... an extensive test menu of highly complex and uniq...y. Owned by the University of Utah, ARUP Laborator...s university teaching hospitals and children's hos...
Keeler Sport Frames
Medicine Products: